argenx SE
argenx SE
Community score
+1.33
Industry: Biotechnology & Pharmaceuticals
Listing country:
Belgium
Year added:
2022
Argenx SE, incorporated in 2008 and headquartered in Breda, the Netherlands, operates primarily in the biotechnology sector focusing on the development of antibody-based therapeutics for cancer and severe autoimmune diseases. Among its pipeline, FcRn antagonists play a significant role, with efgartigimod (ARGX-113) standing out as their lead product candidate targeted for autoimmune conditions such as myasthenia gravis. Although Argenx SE has a global presence in research and development, the sale of its products and services, including the potential commercialization of efgartigimod, is anticipated to be especially significant in the United States and Europe subject to regulatory approvals. (Powered by AI)
Show Company Information
You view a limited profile page without scores and metrics
availability. Subscribing users get to see more advanced data, want to
see it in action? Click on a company you are interested in:
.
Abdulmajeed V. February 22nd, 2024
Henna
B. October 27th, 2023